Using a new method to deliver neuroprotective antibodies for Alzheimer's disease treatment
Official title: CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease
Funded at University of Michigan at Ann Arbor · NIH-11009966 · Data updated 2026-11-12
This study is looking at a new way to help deliver special antibodies to the brain for people with Alzheimer's disease, using a clever method to get past a barrier that usually keeps treatments out, and it will also see how age and the disease itself affect this process in mice.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | April 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $675,215 |
| NIH project number | 5R01AG080016-03 |
| Project ID | NIH-11009966 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults, particularly those aged 65 and above, who are experiencing symptoms of Alzheimer's disease.
✕Less likely to help
Patients under the age of 65 or those without Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on improving the delivery of neuroprotective antibodies to the brain for patients with Alzheimer's disease. The team is developing a bispecific antibody shuttle that can effectively cross the blood-brain barrier, which is a significant challenge in treating this condition. By targeting a specific receptor, CD98hc, the researchers aim to enhance the transport of these antibodies into the brain, potentially leading to better therapeutic outcomes. The study will evaluate how age and disease impact this transport mechanism and will test the effectiveness of this approach in a mouse model of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease by improving the delivery of therapeutic antibodies to the brain.
How similar studies have gone: While the approach of using bispecific antibody shuttles is innovative, previous research has shown promise in similar strategies for enhancing drug delivery across the blood-brain barrier.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Tessier, Peter M — University of Michigan at Ann Arbor
- Study coordinator: Tessier, Peter M
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.